CYP2D6 and breast carcinoma: CYP2D6 NM patients with a first breast cancer and treated with tamoxifen had nearly a 40% lower risk of CBC compared to patients without tamoxifen treatment (AS ≥ 1, RR = 0.63; 95% CI 0.51–0.78).